Accelerate your Drug Development process with Lonza Engine™

As we develop new methods to create more biologically relevant models for research in understanding disease etiology and innovating new treatment options, one of the most requested areas for educational materials is 3D cell models such as organoid and spheroid systems. Thermo Fisher Scientific is proud to present our webinar series on 3D culture & analysis, and more importantly, how you can get started, how to monitor and analyze 3D models and what to do with these once you have successfully cultured your organoid or spheroid model of interest. In this series we will specifically cover the following areas and after taking part in the presentations, hopefully you will be better equipped to answer the basic questions and feel enabled to get started using 3D culture systems.

With Microsoft Azure DevOps, healthcare IT teams get a combination of processes, industry best practices and proven tools to make the most of their DevOps initiatives. The webinar discusses how organizations can leverage it to accelerate DevOps implementation.

In this on-demand webinar, discover the differences between FTIR, NIR and Raman spectroscopy, learn how spectroscopy is applied in quality control labs and hear how implementation of these techniques increased efficiency and minimised costs.

Current diagnostic methods for lower respiratory specimens typically take one to two days to identify most bacterial pathogens. During that time, clinicians must rely on guideline recommendations and clinical diagnosis to guide empiric therapy, which is not optimized based on the patient’s individual pathogen. The BioFire Pneumonia Panel will provide pathogen identification in a much shorter timeframe and may allow clinicians to optimize targeted pathogen-specific therapy sooner. The BioFire Pneumonia Panel is a rapid multiplex-PCR test that identifies 33 targets, including 18 bacteria, 8 viruses and 7 antimicrobial resistance genes from lower respiratory tract specimens in about an hour. It provides semi-quantitative results (in copies/ml) for 15 of the bacterial targets. This new feature provided by multiplex-PCR testing may help clinicians and laboratorians separate colonizing from pathogenic levels of bacteria.